Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879568 | 0.77 | MGLL (0.47) | MGLLALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL13879525 | 0.73 | POLB (0.65) | MGLLALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL13879542 | 0.73 | POLB (0.65) | LMNAPOLBKMT2AGAANPC1 | |
| SCHEMBL13879591 | 0.72 | MGLL (0.47) | MGLLALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL8791401 | 0.69 | KMT2A (0.57) | MGLLALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL242108 | 0.69 | POLB (0.72) | MGLLALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL29439366 | 0.69 | MGLL (1.00) | MGLLALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL141734 | 0.69 | MGLL (1.00) | MGLLALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL8115164 | 0.68 | GAA (0.63) | MGLLALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL25277766 | 0.68 | GAA (0.55) | MGLLALDH1A1LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | MGLL 2140/4885ALDH1A1 1500/4885LMNA 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.